Navigation Links
Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
Date:9/5/2007

- In Patients With BPH, Clinical Benefit After Ozarelix Was Maintained For

Up To Six Months - Pivotal Trials Expected To Commence Before Year End Or Soon Thereafter

IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) today presented updated Phase 2 safety and efficacy data for ozarelix, the Company's drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the 29th Congress of the Societe Internationale d'Urologie in Paris, France.

"The results of this Phase 2 study demonstrate that the effects of a single dosing regimen consisting of two injections on day one and fifteen are maintained for up to six months, which is superior to what is usually seen with currently approved drugs for BPH," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals. "A second 78-patient U.S. Phase 2b study, in which duration of follow-up is 9 months, completed enrollment in May. We look to the Phase 2b data to verify and expand on the experience from the Phase 2 study presented today. We continue to believe that ozarelix could help serve the large unmet medical need for more effective BPH treatments."

The efficacy and safety of ozarelix, a GnRH antagonist, given intramuscularly (IM) was assessed in men with moderate to severe Lower Urinary Tract Symptoms (LUTS) due to BPH in a randomized, double-blind, placebo- controlled, multi-center, Phase 2 dose-ranging study.

Eligible patients entered a 4-week, single blind, placebo run-in to establish baseline IPSS and urine-flow values. Patients (N=144) meeting the inclusion criteria were randomly allocated and received an IM injec
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)...  Recently published clinical studies of Stretta for gastroesophageal ... of evidence. This data has led to significantly expanded ... for sufferers of refractory GERD. The ... therapy as a safe and effective GERD treatment has ... to nearly 50 million Americans. The new clinical studies ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 12, 2007: Progen Industries Limited,(ASX: PGL; NASDAQ: PGLA) is ... data has been accepted for late breaking news,presentation by ... Progen will also be presenting the results of this ... (AACR),Annual Meeting 2007. , ,In expectation of having ...
... Good Safety Profile and Excellent,Pharmacokinetic Properties -, RESEARCH ... BioPharma, Inc., a clinical stage company developing and,commercializing ... today announced top-line results from a Phase I,clinical ... treatment,of depression and anxiety. In this study, Tyrima ...
Cached Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:10/22/2014)... 2014 On October 22, CBS will ... skin diseases both fictional and real. The Charles ... organization committed to advocacy and philanthropy in the battle ... the opportunity to impart truth and clarity about this ... are many misconceptions about Morgellons Disease (MD) ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... reveals there may be a link between hardening of the ... with calcium deposits in the aorta were twice as likely ... in the heart were up to four times more likely ... 60 years or older, who had been diagnosed with having ...
... potential to yield treatments for several human diseases and ... announced they have created 17 new human embryonic stem ... researchers , which is offering the cells, will use ... Their team has been investigating the insulin-producing pancreatic beta ...
... ( an evolution specialist ), helped China's SARS Epidemiology ... fingerprinted virus samples from several dozen infected people and ... provides more evidence that SARS jumps from animals to ... of new cases is crucial, before viral strains have ...
... Ever since organ transplants began, steroids have played a ... their new organ. However, the treatment is not without ... to infections, high blood pressure, elevated blood cholesterol, and ... Belgium suggests children undergoing liver transplants may fare better ...
... has increased rapidly in the last half century, and ... about 50,000 Americans will be diagnosed with it this ... for women between the ages of 30 and 50,// ... yet that artificial sun tanning can be dangerous to ...
... studies have identified genetic activity that appears to be ... a person's perceptions of reality, emotions and thought processes. ... the world's population, typically surface during the late teens ... University in New York and colleagues identified two genes/// ...
Cached Medicine News:Health News:Scientists Have Traced How The SARS Virus evolved 2Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Gene Activity connected to Schizophrenia 2
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
30 degree angled tip with 45 mm tip opening. Made with lock. Manufactured in titanium....
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Folding forceps used for L161U. Manufactured in titanium....
Medicine Products: